Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Does the use of generics of imatinib for chronic myeloid leukaemia jeopardise patient safety?

Dr Zafer Başlar - Istanbul University, Istanbul, Turkey

19 Jun 2014

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

2 Jun 2014

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

2 Jun 2014

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Prof Franco Cavalli, Prof Gordon McVie

1 Jun 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA

31 May 2014

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Dr John Byrd - The Ohio State University, Columbus, USA

31 May 2014

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria

20 May 2014

Myeloma genomics and Immuno-oncology

Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo

15 May 2014

Novel targets and immune based therapy in myeloma

Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel

15 May 2014

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

15 May 2014

Recent advances in mantle cell lymphoma: Expert panel discussion

Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci

13 May 2014

Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

9 May 2014

Video

More from ecancer